Who is sponsoring NCT05411107?

NCT05411107 is sponsored by National Cancer Institute (NCI).

What drugs are being tested in NCT05411107?

Interventions in NCT05411107: Biospecimen Collection, Bronchial Brush Biopsy, Bronchoscopy, Iloprost, Placebo Administration, Questionnaire Administration.

What condition does NCT05411107 study?

NCT05411107 studies Bronchial Epithelial Dysplasia, Chronic Obstructive Pulmonary Disease, Lung Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Tobacco-Related Carcinoma.

Is NCT05411107 still recruiting?

NCT05411107 is currently withdrawn. Last updated 17 May 2024.

Last reviewed 2024-05-17 · How we verify

NCT05411107

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oral Iloprost for the Prevention of Lung Cancer In Former Smokers

Withdrawn Phase 2 Last updated 17 May 2024

What this trial tests

Phase 2 trial testing Biospecimen Collection in Bronchial Epithelial Dysplasia. Withdrawn.

Timeline

1 June 2024

Primary endpoint
1 December 2026

30 June 2027

Quick facts

Lead sponsor	National Cancer Institute (NCI)
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Start date	1 June 2024
Primary completion	1 December 2026
Estimated completion	30 June 2027

Drugs / interventions tested

Biospecimen Collection — full drug profile →
Bronchial Brush Biopsy
Bronchoscopy
Iloprost — full drug profile →
Placebo Administration — full drug profile →
Questionnaire Administration

Conditions studied

Bronchial Epithelial Dysplasia — all drugs for Bronchial Epithelial Dysplasia →
Chronic Obstructive Pulmonary Disease — all drugs for Chronic Obstructive Pulmonary Disease →
Lung Carcinoma — all drugs for Lung Carcinoma →
Stage I Lung Cancer AJCC v8 — all drugs for Stage I Lung Cancer AJCC v8 →

Sponsor

National Cancer Institute (NCI)

Who can join

50 and older, any sex, with Bronchial Epithelial Dysplasia or Chronic Obstructive Pulmonary Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial tests whether oral iloprost works in preventing lung cancer (chemoprevention) in former smokers. Oral iloprost has previously been shown to reduce abnormal lung cells in former smokers, suggesting a clinically significant impact on lung cancer risk. The use of oral iloprost may help keep cancer from forming and reduce abnormal cells in the lung in order to lower the risk of developing lung cancer in former smokers.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The application of patient-derived organoid in the research of lung cancer.
Li Y, Gao X, Ni C, Zhao B, et al · · 2023 · cited 29× · PMID 36696006 · DOI 10.1007/s13402-023-00771-3
Patient-Derived Ex Vivo Cultures and Endpoint Assays with Surrogate Biomarkers in Functional Testing for Prediction of Therapeutic Response.
Tsukamoto Y, Hirashita Y, Shibata T, Fumoto S, et al · · 2023 · cited 3× · PMID 37627132 · DOI 10.3390/cancers15164104

Verify or expand the search:

Other trials of Biospecimen Collection

Trials testing the same drug.

NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting

Other National Cancer Institute (NCI) trials

Trials by the same sponsor.

NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05411107 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
Last refreshed: 17 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05411107.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing